Jefferies Maintains Buy on Protagonist Therapeutics, Raises Price Target to $118
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
Jefferies analyst Roger Song maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $95 to $118.
Jefferies analyst Roger Song maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $95 to $118.